Zacks Research Issues Pessimistic Outlook for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at Zacks Research dropped their Q3 2026 earnings estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, February 3rd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter, down from their previous estimate of $0.04. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2027 earnings at $0.01 EPS and FY2027 earnings at $0.26 EPS.

A number of other equities analysts have also weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Piper Sandler initiated coverage on Esperion Therapeutics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.20.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $3.18 on Wednesday. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $4.18. The company has a market capitalization of $760.21 million, a PE ratio of -6.36, a P/E/G ratio of 0.72 and a beta of 1.09. The company has a fifty day moving average of $3.62 and a 200 day moving average of $2.88.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The business had revenue of $87.31 million for the quarter, compared to analyst estimates of $78.33 million.

Institutional Trading of Esperion Therapeutics

Several institutional investors have recently modified their holdings of ESPR. Vanguard Group Inc. increased its stake in shares of Esperion Therapeutics by 23.6% during the fourth quarter. Vanguard Group Inc. now owns 14,945,454 shares of the biopharmaceutical company’s stock worth $55,298,000 after purchasing an additional 2,853,005 shares in the last quarter. Two Seas Capital LP lifted its stake in Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after buying an additional 3,024,104 shares in the last quarter. Marshall Wace LLP boosted its holdings in Esperion Therapeutics by 46.2% in the 2nd quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock worth $5,206,000 after buying an additional 1,679,294 shares during the last quarter. Geode Capital Management LLC increased its stake in Esperion Therapeutics by 3.1% during the 2nd quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock worth $4,513,000 after buying an additional 137,691 shares in the last quarter. Finally, AIGH Capital Management LLC raised its holdings in shares of Esperion Therapeutics by 33.3% during the fourth quarter. AIGH Capital Management LLC now owns 4,000,000 shares of the biopharmaceutical company’s stock valued at $14,800,000 after acquiring an additional 1,000,000 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Insider Transactions at Esperion Therapeutics

In related news, CFO Benjamin Halladay sold 7,337 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the completion of the sale, the chief financial officer owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. The trade was a 1.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 15,543 shares of company stock valued at $55,709. 1.70% of the stock is currently owned by company insiders.

Key Headlines Impacting Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Zacks sharply raised its Q4 2025 estimate to $0.32 from $0.02 — a material upward revision that signals stronger-than-expected near-term profitability potential and could support re-rating if sustained.
• Positive Sentiment: Zacks bumped FY2027 to $0.26 from $0.20 and FY2026 to ($0.01) from ($0.13) — improved multi-year earnings visibility that may justify higher valuation expectations if operational results follow.
• Positive Sentiment: Several quarters were revised up: Q4 2027 to $0.14 (from $0.11), Q2 2027 to $0.08 (from $0.03), Q4 2026 to $0.03 (from $0.01), Q1 2026 to ($0.04) (from ($0.14)), and Q2 2026 to ($0.01) (from ($0.05)) — a cluster of upward revisions that reduce expected near-term losses and point to improving trend across periods.
• Negative Sentiment: Zacks trimmed Q3 2026 and Q3 2027 estimates (both to $0.01 from higher prior marks) — these downgrades introduce some quarter-to-quarter volatility risk and suggest not all near-term quarters are improving, which can pressure sentiment.
• Neutral Sentiment: Consensus still shows a negative current-year EPS (-$0.29 per consensus), so despite Zacks’ upgrades, overall market expectations remain mixed; investors will likely look for upcoming revenue cadence, margins, and execution to validate the upgrades.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.